dependent repression. The authors also report that the Nurr1-CoREST interaction is stimulated by phosphorylation of Nurr1 by Nemo-like kinase. Lastly, ChIP analysis of iNOS promoter occupancy following stimulation by LPS suggests a temporal model of transrepression in which p65 binding precedes Nurr1 association, which is followed by recruitment of CoREST to the complex.
The Saijo et al. study provides important insights into the ability of Nurr1 and CoREST to modulate neuroinflammation. The work unravels molecular mechanisms that may underlie human neurological disease and opens the door for future work on inflammatory signaling in the brain. These studies also provide a better understanding of how transrepression is achieved at the molecular level. Interestingly, certain components of the transrepression mechanism appear to be conserved between different nuclear receptors, such as the requirement for sumoylation and the interaction with NF-κB proteins and corepressors. At the same time, Saijo et al. illustrate how different nuclear receptors utilize distinct corepressor complexes to repress gene expression in a signal-and contextdependent manner.
Finally, the work prompts a number of interesting questions to be addressed in future studies. For example, the three NR4A receptors (Nurr77, Nurr1, and Nor1) regulate overlapping target genes in some cell types. Do Nurr77 and Nor1 also interact with CoREST in response to inflammatory signals? What is the relative contribution of transrepression and direct gene activation in NR4A-dependent regulation of inflammation? Sumoylation appears to be a critical component of the transrepression mechanism. In the PPAR and LXR transrepression pathways, sumoylation of the receptor is triggered by ligand binding. Is Nurr1 sumoylation responsive to other cellular signals in addition to IL-1β? Is the Nurr1/CoREST transrepression pathway intact in monocytes and macrophages, and if so, does this repression pathway also have a role in peripheral inflammation? Lastly, there is strong evidence that neuroinflammation contributes to the pathogenesis of a number of diseases, including Alzheimer's disease and multiple sclerosis. It will be important to determine if this repression pathway is altered in these diseases and whether NR4A receptors might represent potential therapeutic targets.
Cancer progression from the primary phase to the metastatic phase represents one of the key determinants of prognosis and outcome for cancer patients. However, the mechanistic details behind the metastatic spread of cancer remain obscure. Although the cytokine transforming growth factor β (TGFβ) has emerged as a major player in the metastatic process, it has seemingly contradictory functions. Ordinarily a tumor suppressor that mediates growth arrest and apoptosis, TGFβ appears to take on the opposite role in end-stage tumors where it promotes metastasis (Padua and Massague, 2009 Although much is known about the genes that promote metastasis, few suppressors of metastasis have been found. Adorno et al. (2009) now identify p63 as a potent suppressor of metastasis and uncover an intricate mechanism for the inactivation of metastasis in cancer cells in response to transforming growth factor β.
the related p63 protein, thus uncovering a new role for p63 in the negative regulation of metastasis. The starting point in uncovering this mechanism was a simple experiment to determine whether the cellular response to TGFβ differed between cells expressing wild-type and mutant p53. Adorno et al. confirm that wild-type p53 plays an important role in the tumor-suppressive function of TGFβ by promoting growth arrest and upregulation of p21. However, they unexpectedly find that in response to TGFβ, mutant p53 induces a dramatic alteration in cell morphology that is indicative of increased migration capacity. Further analysis by the authors reveals that mutant p53 is responsible for the ability of cultured human breast cancer cells to migrate, invade, and metastasize in both in vitro and in vivo assays. Building on previous observations that mice lacking one copy of the p53 gene and one copy of either the p63 or p73 gene developed tumors with metastatic potential (Flores et al., 2005) , Adorno and colleagues show that inactivation of p63 promotes the oncogenic function of TGFβ. In contrast, overexpression of p63 strongly inhibits the metastatic potential conferred by mutant p53, indicating that the antimetastatic function of p63 lies downstream of mutant p53.
Adorno et al. find that Smad proteins act as an essential scaffold for mutant p53 to sequester p63, possibly disrupting the function of p63 as a transcriptional activator. The formation of a ternary mutant p53/Smad/p63 complex is exquisitely dependent upon the level of TGFβ signaling. As the level of TGFβ increases, mutant p53 titrates away increasing amounts of free p63, thereby possibly preventing p63 from binding to the promoters of its transcriptional targets. Intriguingly, in addition to requiring TGFβ signaling, the formation of a ternary mutant p53/Smad/p63 complex also requires oncogenic Ras (RasV12) signaling in a manner similar to Ras activation of wild-type p53 (Cordenonsi et al., 2007) (Figure 1 ). Though this mechanism of p63 regulation in the context of mutant p53 is compelling, it should be noted that the role of the p63/Smad complex in normal cells remains to be established. Indirect evidence suggests that wild-type p53 does not affect the antimetastatic function of p63, but the question remains whether a wild-type p53/Smad/p63 complex dependent on Ras and TGFβ signaling also exists. This complex could function in tumor suppression in normal cells as well as play a role in regulating tumor cells in the presence of aberrant Ras activation (Figure 1) .
To better understand how p63 inactivation promotes metastasis, Adorno et al. identify essential targets of mutant p53 and TGFβ that could be responsible for the metastatic potential. Their analysis reveals a restricted set of five genes that are coregulated by both mutant p53 and TGFβ. Of these, the genes encoding Sharp-1 (BHLHE41) and cyclin G2 (CCGN2) are p63 targets whose expression is impaired upon p63 inactivation. Inactivation of either gene restores TGFβ-dependent promigratory activities in cultured p53-deficient breast tumor cells, suggesting that their gene products mediate the antimetastatic functions of p63. It remains to be determined how Sharp-1 and cyclin G2 act to inhibit the metastatic process. Cyclin G2 is known to be upregulated in response to DNA damage and can promote cell-cycle arrest (Arachchige Don et al., 2006) , a function typical of a tumor suppressor. However, a direct role in metastasis for Sharp-1, a regulator of circadian oscillation and feedback (Rossner et al., 2008) , is not immediately apparent. Provocatively, although neither of these genes has been previously identified in known gene expression signatures for breast cancer metastasis (Fan et al., 2006) , their prognostic value holds in analyses of datasets from 1200 primary breast cancers and associated clinical data. The authors categorize patients in those datasets into two groups that have either high or low expression of Sharp-1 or cyclin G2. Survival analysis indicates that "low-expression" groups have a markedly higher probability of cancer recurrence than "high-expression" groups. Remarkably, this simple stratification of patients based on a two gene "minimal signature" was comparable to the stratification based on a 70 gene breast cancer metastasis expression profile (Fan et al., 2006) .
Taken together, these new findings are of tremendous value. Although the published literature points to a large number of possible metastasis enhancers, our current knowledge on specific metastasis suppressors is sparse. Hence, the identification of p63 is a seminal finding that could launch a race to identify additional suppressors of metastasis. Adorno et al. clearly demonstrate that loss of p63 function is critical to TGFβ-mediated metastatic potential. However, their findings do not fully address why cancer cells would develop such an intricate mechanism to inactivate the protein rather than simply mutating or losing the gene during tumor progression. Clues to why cells maintain the p63 gene may come from its role as a key determinant of epithelial stem cell proliferative potential (Senoo et al., 2007) . Indeed, an ability to modulate p63 activity in a quantitative manner according to TGFβ signaling would allow regulation of epithelial cell fate within the developing tumor. A high level of TGFβ signaling within the primary tumor would promote p63 inactivation to allow for acquisition of metastatic potential. However, after migration of primary tumor cells to distant metastatic sites, decreased TGFβ signals at those sites would allow for reactivation of p63 function, thereby enabling efficient propagation of cells to form the secondary tumor.
Another important implication of Adorno et al.'s study is the proposition of a minimal metastatic signature involving the expression of genes encoding Sharp-1 and cyclin G2. The fact that expression of these two genes alone can efficiently stratify cancer patients and predict the metastatic potential of their tumors represents a tremendous advance over the more elaborate metastatic signatures that have been proposed to date (Fan et al., 2006) . Although a TGFβ signature in a subset of breast tumors can predict metastatic spreading to the lung (Padua et al., 2008) , Sharp-1 and cyclin G2 may represent a more effective "minimal signature." This is because they are identified through the comparative analysis of microarray datasets selected on the basis of mechanistic insights (for example, the gene expression signature of cells in the presence or absence of TGFβ compared to that of cells harboring wild-type or mutant p53) rather than on the basis of metastatic outcome and tumor type. However, feedback from the cancer community will be important to understand if such a minimal signature holds not only for breast cancers but also for epithelial cancers derived from other organs.
Finally, from a therapeutic perspective, it will be interesting to understand how to take advantage of the mechanistic details unveiled by Adorno et al. To date, the idea of anti-TGFβ cancer therapies has been met with caution due to the dual nature of the TGFβ signaling pathway in promoting both tumor suppression and metastasis. However, the targeting of the mutant p53/ Smad/p63 complex now represents one potential option for therapeutic intervention. Small molecules that disrupt the binding of mutant p53 to Smad/p63 may promote p63 release from the complex to inhibit metastasis. Similarly, inhibitors of CK1δ/ε, the kinase proposed to phosphorylate p53 downstream of receptor tyrosine kinase/Ras signaling, could also disrupt the p53/Smad/p63 complex and are already in clinical trials. Thus, beyond shedding light on the metastatic process, the work of Adorno et al. underscores the potential clinical value in identifying and characterizing metastatic suppressors through mechanistic study.
